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Abstract
Background:
18F-FDG PET/CT is widely utilized in the management of cancer patients. The aim of this paper was
to comprehensively describe the specific methodology utilized in our single-institution cumulative retrospective
experience with a multimodal imaging and detection approach to
18F-FDG-directed surgery for known/suspected
malignancies.
Methods: From June 2005-June 2010, 145 patients were injected with
18F-FDG in anticipation of surgical
exploration, biopsy, and possible resection of known/suspected malignancy. Each patient underwent one or more
of the following: (1) same-day preoperative patient diagnostic PET/CT imaging, (2) intraoperative gamma probe
assessment, (3) clinical PET/CT specimen scanning of whole surgically resected specimens (WSRS), research
designated tissues (RDT), and/or sectioned research designated tissues (SRDT), (4) micro PET/CT specimen scanning
of WSRS, RDT, and/or SRDT, (5) total radioactivity counting of each SRDT piece by an automatic gamma well
counter, and (6) same-day postoperative patient diagnostic PET/CT imaging.
Results: Same-day
18F-FDG injection dose was 15.1 (± 3.5, 4.6-26.1) mCi. Fifty-five same-day preoperative patient
diagnostic PET/CT scans were performed. One hundred forty-two patients were taken to surgery. Three of the
same-day preoperative patient diagnostic PET/CT scans led to the cancellation of the anticipated surgical
procedure. One hundred forty-one cases utilized intraoperative gamma probe assessment. Sixty-two same-day
postoperative patient diagnostic PET/CT scans were performed. WSRS, RDT, and SRDT were scanned by clinical
PET/CT imaging and micro PET/CT imaging in 109 and 32 cases, 33 and 22 cases, and 49 and 26 cases,
respectively. Time from
18F-FDG injection to same-day preoperative patient diagnostic PET/CT scan, intraoperative
gamma probe assessment, and same-day postoperative patient diagnostic PET/CT scan were 73 (± 9, 53-114), 286
(± 93, 176-532), and 516 (± 134, 178-853) minutes, respectively. Time from
18F-FDG injection to scanning of WSRS,
RDT, and SRDT by clinical PET/CT imaging and micro PET/CT imaging were 389 (± 148, 86-741) and 458 (± 97, 272-
656) minutes, 619 (± 119, 253-846) and 661 (± 117, 433-835) minutes, and 674 (± 186, 299-1068) and 752 (± 127,
499-976) minutes, respectively.
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planning and execution, and determination of completeness of surgical resection.
Background
18F-fluorodeoxyglucose (
18F-FDG) positron emission
tomography/computed tomography (PET/CT) is widely
used in the clinical management of cancer patients and
has become the cornerstone of diagnostic imaging, sta-
ging, follow-up surveillance, and monitoring of ongoing
therapy for a wide variety of malignancies [1-7]. In this
regard, there has been increased interest and growth in
clinical research directed towards the use of
18F-FDG
for the intraoperative detection of known and occult
malignant disease during cancer surgery [8-48]. The
application of
18F-FDG for intraoperative detection dur-
ing cancer surgery was first described in 1999 for color-
ectal cancer [8]. Since that time, a significant portion of
this ongoing work related to the use of
18F-FDG for
intraoperative detection during cancer surgery has been
conducted at The Ohio State University and has been
directed toward multiple solid malignancies
[8-10,22-24,28-33,36,37,40]. Collectively, such efforts
have been directed toward colorectal cancer, melanoma,
lymphoma, breast cancer, gynecologic malignancies,
head and neck malignancies, and lung cancer [8-48].
The motivation behind using
18F-FDG for intraoperative
detection during cancer surgery has been multifactorial,
including exploring its applicability for real-time intrao-
perative staging, surgical planning and execution, and
determination of completeness of surgical resection for
18F-FDG-avid lesions.
In 2007, we first reported upon our ongoing efforts to
formulate a truly multimodal imaging and detection
approach to
18F-FDG-directed surgery [23,32,36,40]. In
the general schema for this multimodal approach,
patients undergoing same-day intravenous administra-
tion of
18F-FDG were subjected to one or more of a
variety of
18F-FDG-related diagnostic procedures,
including (1) same-day preoperative patient diagnostic
PET/CT imaging, (2) intraoperative gamma probe
assessment, (3) clinical PET/CT specimen scanning of
whole surgically resected specimens (WSRS), research
designated tissues (RDT), and/or sectioned research
designated tissues (SRDT) (Table 1), (4) micro PET/CT
specimen scanning of WSRS, RDT, and/or SRDT, (5)
total radioactivity counting of each SRDT piece by an
automatic gamma well counter, and (6) same-day post-
operative patient diagnostic PET/CT imaging. Herein,
we have comprehensively described the specific metho-
dology utilized in our single-institution cumulative ret-
rospective experience with a multimodal imaging and
detection approach to
18F-FDG-directed surgery for
patients with known or suspected malignancies, in order
to assess its technical and logistic feasibility for real-
time intraoperative staging, surgical planning and execu-
tion, and determination of completeness of surgical
resection for
18F-FDG-avid lesions detected in patients
who are deemed as appropriate surgical candidates.
Methods
Patient population
This retrospective review, representing our cumulative
experience with a multimodal imaging and detection
approach to
18F-FDG-directed surgery for known or sus-
pected malignancies from June 2005 to June 2010 at the
Arthur G. James Cancer Hospital and Richard J. Solove
Research Institute of The Ohio State University Medical
Center (OSUMC), was approved by the OSUMC Cancer
Institutional Review Board.
All patients evaluated from this retrospective cumula-
tive experience were planned for surgical exploration,
biopsy, and possible resection within the operating
room of a known or suspected malignancy, based upon
the standard of care management for their particular
disease entity. All patients evaluated had to have a
known or suspected malignancy, as well as had to be ≥
18 years of age, non-pregnant, and healthy enough to be
considered for surgical exploration, biopsy, and possible
resection within the operating room. Written informed
consent was obtained from all patients on the day of
surgery after all aspects of the proposed multimodal
approach were fully discussed with them and prior to
initiation of any
18F-FDG-directed procedures.
Schema of multimodal imaging and detection approach
to
18F-FDG-directed surgery
For this multimodal schema, patients underwent one or
more of a variety of
18F-FDG-related diagnostic proce-
dures, including (1) same-day preoperative patient diag-
nostic PET/CT imaging, (2) intraoperative gamma probe
assessment, (3) clinical PET/CT scanning of whole sur-
gically resected specimens (WSRS), research designated
tissues (RDT), and/or sectioned research designated tis-
sues (SRDT) (Table 1), (4) micro PET/CT scanning of
WSRS, RDT, and/or SRDT, (5) total radioactivity count-
ing of each SRDT piece by an automatic gamma well
counter, and (6) same-day postoperative patient diagnos-
tic PET/CT imaging. Four examples of this multimodal
imaging and detection approach to
18F-FDG-directed
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components of this schema have been previously
described [23,32].
In general, patients underwent whole body diagnostic
PET/CT scanning either prior to the date of their
18F-
FDG-directed surgery or on the day of their
18F-FDG-
directed surgery. The
18F-FDG dosing used for all whole
body diagnostic PET/CT scans was based upon stan-
dard-of-care practice guidelines recommended in the
United States [49,50]. All such whole body diagnostic
PET/CT scans were reviewed and interpreted by a
board certified nuclear medicine physician and a surgical
oncologist prior to their
18F-FDG-directed surgery. Dur-
ing the time frame of this retrospective, cumulative
experience at OSUMC, three different diagnostic PET/
CT imaging units were utilized, and included: (1) Sie-
mens Biograph 16 (Siemens, Knoxville, Tennessee, (2)
Phillips Gemini TF (Philips, Amsterdam, Netherlands),
and (3) Siemens Biograph mCT (Siemens, Knoxville,
Tennessee).
On the date of the anticipated
18F-FDG-directed sur-
gery, all patients were intravenously injected with
18F-
FDG, based upon standard-of-care practice guidelines
recommended for
18F-FDG dosing for whole body diag-
nostic PET/CT scanning in the United States [49,50].
After receiving their same-day
18F-FDG injection,
patients either: (1) underwent a same-day preoperative
patient diagnostic PET/CT scan and were then taken to
Table 1 Tissues collected at the time of biopsy and resection of a known or suspected malignancy at the time of
18F-FDG-directed surgery
Tissue designation Abbreviation Description of tissue designation
Whole Surgically Resected
Specimen
WSRS Intact tissue removed as a biopsy specimen or as a resected specimen
Research Designated Tissue RDT An approximately 5 mm thick representative portion of tissue from the WSRS which contained both
gross tumor and normal appearing tissue
Sectioned Research
Designated Tissue
SRDT Sectioned pieces of tissue that resulted when the RDT was cut into multiple portions of tissue that
were of a size that would allow each such sectioned piece of tissue to fit into an individual pathology
cassette (i.e., approximately 1.0 cm × 1.0 cm × 0.5 cm)
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Figure 1 Segment 7 hepatic metastasis from colorectal cancer: (a) Preoperative patient diagnostic PET/CT scan demonstrating an
18F-FDG-
avid lesion in the liver (red circle). (b) Postoperative patient diagnostic PET/CT demonstrating complete removal of the
18F-FDG-avid lesion (red
circle). (c) Digital photo of the WSRS (i.e., segment 7 liver resection specimen), visualizing the hepatic metastasis (red oval). (d) Clinical PET/CT
specimen image and (e) micro PET/CT specimen image of the WSRS, demonstrating the
18F-FDG-avid lesion (red oval). (f) Digital photo
depicting the first phase of the pathologic processing that produced the RDT, which consists of a single 0.5 cm slice through the hepatic
metastasis. (g) Clinical PET/CT specimen image and (h) micro PET/CT specimen image of the RDT, demonstrating the
18F-FDG-avid lesion that
corresponds to the hepatic metastasis. (i) Digital photo after sectioning of the RDT into five pieces of tissue, designated as SRDT, with two pieces
containing visible tumor. (j) Clinical PET/CT specimen image and (k) micro PET/CT image of the SRDT, demonstrating
18F-FDG avidity in the two
pieces that corresponds to the hepatic metastasis. (l) H&E stained, whole-mount slide (0.4× magnification) of the specific SRDT piece that is
highlighted in the red rectangle in (i), (j), and (k), demonstrating histologic confirmation of a colorectal cancer hepatic metastasis and the
corresponding location of tumor within this specific SRDT piece. Each division of the hatched line in (c), (f), and (i) represents 1 cm.
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operating room for their
18F-FDG-directed surgery or
(2) were directly taken to the preoperative holding area
before proceeding to the operating room for their antici-
pated
18F-FDG-directed surgery.
Intraoperatively, potential sites of tumor were
attempted to be localized by classical surgical techniques
of visual inspection and palpation. Thereafter, potential
sites of tumor were attempted to be localized by intrao-
perative gamma probe assessment. During the time
frame of this retrospective, cumulative experience, three
different handheld gamma detection probe systems were
utilized, and included: (1) Neoprobe 1000
® (Neoprobe
Corporation, Dublin, Ohio), (2) Neoprobe 2000
® (Neop-
robe Corporation, Dublin, Ohio), and (3) RMD Naviga-
tor™ GPS (RMD Instruments Corp, Watertown,
Massachusetts).
The surgeon then proceeded with biopsy and possible
resection of the known or suspected malignancy, based
upon the standard of care management for the particu-
lar disease entity. Whole surgically resected specimens
(WSRS), once removed by the surgeon, were computer
documented and accessioned by the operating room
nursing staff, and were then taken directly to the
Pathology Department for initiation of specimen proces-
sing. As per hospital policy, assignment of a pathology
accession number and gross examination of each speci-
men was performed and documented by a surgical
pathology technologist.
When technically feasible, WSRS were then taken to
the PET/CT suite of the Radiology Department and
mounted on a rectangular one-half inch thick slab of
paraffin. Digital photographs of the WSRS were taken to
document visible appearance of the WSRS with the
appearance of the WSRS on clinical PET/CT specimen
imaging and/or micro PET/CT specimen imaging. PET/
CT imaging was then performed on the WSRS using
the same diagnostic PET/CT imaging unit that was used
for the same-day preoperative patient diagnostic PET/
CT scan, if performed. Images were processed and
reviewed for quality and for determination of the pre-
sence or absence of
18F-FDG-avid foci. This was then
correlated to the
18F-FDG-avid foci originally seen on
the whole body diagnostic PET/CT scan done prior to
the date of their
18F-FDG-directed surgery or on the day
of their
18F-FDG-directed surgery. In selected cases,
micro PET/CT specimen imaging was then performed
on WSRS utilizing the Inveon micro PET/CT scanner
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Figure 2 Right lower lobe lung cancer: (a) Preoperative patient diagnostic PET/CT scan demonstrating an
18F-FDG-avid lesion in the right
lower lobe (red circle). (b) Postoperative patient diagnostic PET/CT demonstrating complete removal of the
18F-FDG-avid lesion (red circle). (c)
Digital photo of the WSRS (i.e. right lower lobectomy specimen), visualizing the lung cancer (red circle). (d) Clinical PET/CT specimen image of
the WSRS, demonstrating the
18F-FDG-avid lesion (red circle). (e) Digital photo depicting the first phase of the pathologic processing that
produced the RDT, which consists of a single 0.5 cm slice through the lung cancer. (f) Clinical PET/CT specimen image and (g) micro PET/CT
specimen image of the RDT, demonstrating the
18F-FDG-avid lesion that corresponds to the lung cancer. (h) Digital photo after sectioning of the
RDT into six pieces of tissue, designated as SRDT, with four pieces containing visible tumor. (i) Clinical PET/CT specimen image and (j) micro PET/
CT image of the SRDT, demonstrating
18F-FDG avidity in the four pieces that corresponds to the lung cancer. (k) H&E stained, whole-mount slide
(0.4× magnification) of the specific SRDT piece that is highlighted in the red rectangle in (h), (i), and (j), demonstrating histologic confirmation of
the lung cancer and the corresponding location of tumor within this specific SRDT piece. Each division of the hatched line in (c), (e), and (h)
represents 1 cm.
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Solutions, Knoxville, Tennessee), if the WSRS were
small enough to fit into the 12 cm bore of the micro
PET/CT scanner unit.
The WSRS was then returned to the Pathology
Department for further specimen processing. In selected
cases, from the WSRS, an approximately 5 mm thick
representative research designated tissue specimen was
harvested which contained both gross tumor and nor-
mal appearing tissue and was defined as research desig-
nated tissues (RDT). This 5 mm thickness was chosen
to accommodate the depth of a standard pathology cas-
sette. The RDT was returned to the PET/CT suite of
the Radiology Department, digitally photographed to aid
in localization and orientation, and again underwent
clinical PET/CT specimen imaging and/or micro PET/
CT specimen imaging described above for the WSRS.
In selected cases, the RDT was then cut into multiple
pieces of a size that would allow each such piece to fit
into individual pathology cassettes (i.e., approximately
1.0 cm × 1.0 cm × 0.5 cm). The resultant pieces of tis-
sue were designated as sectioned research designated
tissues (SRDT). These cuts were made such that at least
one SRDT piece contained a visible transition from
grossly visible tumor to grossly normal appearing tissue.
The SRDT pieces were digitally photographed to docu-
ment the location and orientation of each SRDT piece
as it related to the previous RDT. Each side of an indivi-
dual SRDT piece was inked in a different color for later
identifying the original orientation of each SRDT piece
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Figure 3 Left axillary recurrence from breast cancer: (a) Preoperative patient diagnostic PET/CT scan demonstrating an
18F-FDG-avid lesion in
the left axilla (red circle). (b) Postoperative patient diagnostic PET/CT demonstrating complete removal of the
18F-FDG-avid lesion (red circle). (c)
Digital photo of the WSRS (i.e., left axillary lymph node dissection specimen), with the white circle corresponding to a suspicious palpable lymph
node that is to be further processed. (d) Clinical PET/CT specimen image and (e) micro PET/CT specimen image of the WSRS, with the red circle
demonstrating the
18F-FDG-avid lesion that is to be further processed. (f) Digital photo depicting the first phase of the pathologic processing that
produced the RDT, which consists of a single 0.5 cm slice through a piece of tissue containing the suspicious palpable lymph node. (g) Clinical PET/
CT specimen image and (h) micro PET/CT specimen image of the RDT, demonstrating the
18F-FDG-avid lesion that corresponds to the piece of
tissue containing the suspicious palpable lymph node. (i) Digital photo after sectioning of the RDT into four pieces of tissue, designated as SRDT,
with visible tumor seen within the piece of tissue shown in the red square. (j) Clinical PET/CT specimen image and (k) micro PET/CT image of the
SRDT, demonstrating
18F-FDG avidity within the piece of tissue shown in the red square that corresponds to the visible tumor within the previously
processed portion of the suspicious palpable lymph node. (l) H&E stained, whole-mount slide (0.4× magnification) of the specific SRDT piece that is
highlighted in the red square in (i), (j), and (k), demonstrating histologic confirmation breast cancer within the corresponding previously processed
portion of the suspicious palpable lymph node. Each division of the hatched line in (c), (f), and (i) represents 1 cm.
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processing, sectioning and H&E staining. As with the
WSRS and RDT, the SRDT pieces underwent clinical
PET/CT specimen imaging and/or micro PET/CT speci-
men imaging. Each SRDT piece was then individually
weighed and placed into an automatic gamma well
counter (1282 Compugamma CS, LKB Wallac Corpora-
tion, Turku, Finland) to determine the total radioactivity
within each SRDT piece. Each SRDT piece was then
placed into its own individual pathology cassette, labeled
such that its orientation could be maintained, and
returned to the Pathology Department for standard
processing.
At the completion of the
18F-FDG-directed surgery,
patients were taken to the postanesthesia care unit for
standard postoperative recovery. Thereafter, if deter-
mined to be medically safe, patients were transported to
the PET/CT suite of the Radiology Department for
same-day postoperative patient diagnostic PET/CT ima-
ging utilizing the same-day
18F-FDG injection given ear-
lier in the day and with no additional
18F-FDG
administered. The same-day postoperative patient diag-
nostic PET/CT scan was performed in a similar fashion
as the same-day preoperative patient diagnostic PET/CT
scan, using the same imaging unit, but reducing the
field of imaging to the region of the body where the
18F-FDG-avid foci were originally located on the preo-
perative patient diagnostic PET/CT scan.
All standard precautions were followed regarding
radiation safety and monitoring, and were in compli-
ance with the regulatory standards and policies set
forth by OSUMC Radiation Safety Program of The
Office of Environmental Health and Safety for radionu-
clide administration, and have been previously
described [33].
Statistical analysis
Results were expressed as mean (± SD, range). The soft-
ware program IBM SPSS
® 19 for Windows
® (SPSS, Inc.,
Chicago, Illinois) was used for the data analysis.
Results
A total of 145 patients were intravenously injected with
18F-FDG in anticipation for proceeding to the operating
room on that same day for surgical exploration, biopsy,
and possible resection of a known or suspected malig-
nancy. This consisted of 98 females and 47 males. There
were 134 Caucasian, eight African-American, and three
Asian patients. Mean patient age was 57 (± 12, range
21-83) years. For all 145 participating patients, mean
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Figure 4 Rectosigmoid colon recurrence from cervical cancer: (a) Preoperative patient diagnostic PET/CT scan demonstrating an
18F-FDG-
avid lesion in the rectosigmoid colon (red circle). (b) Postoperative patient diagnostic PET/CT demonstrating complete removal of the
18F-FDG-
avid lesion (red circle). (c) Digital photo of the WSRS (i.e., segmental rectosigmoid colon resection specimen), demonstrating the area of the
rectosigmoid colon recurrence (white oval). (d) Clinical PET/CT specimen image and (e) micro PET/CT specimen image of the WSRS,
demonstrating the
18F-FDG-avid lesion (red oval). (f) Digital photo depicting the first phase of the pathologic processing that produced the RDT,
which consists of a single 0.5 cm slice through the rectosigmoid colon recurrence. (g) Clinical PET/CT specimen image and (h) micro PET/CT
specimen image of the RDT, demonstrating the
18F-FDG-avid lesion that corresponds to the rectosigmoid colon recurrence. (i) Digital photo after
sectioning of the RDT into four pieces of tissue, designated as SRDT, with two pieces containing visible tumor. (j) Clinical PET/CT specimen
image and (k) micro PET/CT image of the SRDT, demonstrating
18F-FDG avidity in the two pieces that corresponds to the rectosigmoid colon
recurrence. (l) H&E stained, whole-mount slide (0.4× magnification) of the specific SRDT piece that is highlighted in the red square in (i), (j), and
(k), demonstrating histologic confirmation of the rectosigmoid colon recurrence of cervical cancer and the corresponding location of tumor
within this specific SRDT piece. Each division of the hatched line in (c), (f), and (i) represents 1 cm.
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18F-FDG injection dose was 15.1 (± 3.5, range
4.6-26.1) mCi.
Of those 145 patients, a preoperative patient diagnos-
tic PET/CT scan was done prior to the date of their
anticipated
18F-FDG-directed surgery in 90 patients. In
the remaining 55 patients, a preoperative patient diag-
nostic PET/CT scan was done on the same day as the
anticipated
18F-FDG-directed surgery. For those 90
patients having their preoperative patient diagnostic
PET/CT scan done prior to the day of their anticipated
18F-FDG-directed surgery, mean
18F-FDG injection dose
for their prior preoperative patient diagnostic PET/CT
scan was 14.3 (± 1.5, range 8.4-16.5) mCi, time from
18F-FDG injection to the preoperative patient diagnostic
PET/CT scan was 80.6 (± 18, range 43-179) minutes,
and mean duration of time from preoperative patient
diagnostic PET/CT scan to the date of the anticipated
18F-FDG-directed surgery was 24 (± 18, range 1-92)
days. For those 55 patients undergoing a same-day preo-
perative patient diagnostic PET/CT scan, mean same-
day
18F-FDG injection dose was 16.4 (± 2.4, range 11.7-
21.8) mCi and mean time from same-day
18F-FDG injec-
tion to their same-day preoperative patient diagnostic
PET/CT scan was 73 (± 9, range 53-114) minutes.
Among the 145 patients intravenously injected with
18F-FDG in anticipation for proceeding to the operating
room on that same day for surgical exploration, biopsy,
and possible resection of a known or suspected malig-
nancy, 142 were eventually taken to surgery on that
same day. However, three of the same-day preoperative
patient diagnostic PET/CT scans led to the cancellation
of the anticipated surgical procedure. In two of these
cases, same-day preoperative patient PET/CT scan
demonstrated inoperable, widespread metastatic disease.
In the other case, there was interval complete resolution
of
18F-FDG avidity seen at the time of same-day preo-
perative patient diagnostic PET/CT scan as compared
18F-FDG avidity seen on a previously performed patient
PET/CT scan.
Intraoperative gamma probe assessment was per-
formed on 141 patients taken to the operating room for
18F-FDG-directed surgery. In the one case in which
intraoperative gamma probe assessment was not per-
formed, upon initial surgical exploration, it was noted
that diffuse carcinomatosis was present, and resultantly,
further surgical intervention was aborted. Mean time
from same-day
18F-FDG injection to intraoperative
gamma probe assessment was 286 (± 93, range 176-532)
minutes.
WSRS were imaged by clinical PET/CT specimen
scanning and micro PET/CT specimen scanning scan in
109 cases and 32 cases, respectively. Mean time from
same-day
18F-FDG injection to scanning of WSRS by
clinical PET/CT specimen scanning and micro PET/CT
specimen scanning was 389 (± 148, range 86-741) min-
utes and 458 (± 97, range 272-656) minutes,
respectively.
RDT were imaged by clinical PET/CT specimen scan-
ning and micro PET/CT specimen scanning in 33 cases
and 22 cases, respectively. Mean time from same-day
18F-FDG injection to scanning of RDT by clinical PET/
CT specimen scanning and micro PET/CT specimen
scanning was 619 (± 119, range 253-846) minutes and
661 (± 117, range 433-835) minutes, respectively.
SRDT pieces were imaged by clinical PET/CT speci-
men scanning and micro PET/CT specimen scanning in
49 cases and 26 cases, respectively. Mean time from
same-day
18F-FDG injection to scanning of SRDT pieces
by clinical PET/CT specimen scanning and micro PET/
CT specimen scanning was 674 (± 186, range 299-1068)
minutes and 752 (± 127, range 499-976) minutes,
respectively. Tissue counting of individual SRDT pieces
was performed on an automatic gamma well counter in
45 cases. Mean time from same-day
18F-FDG injection
to performance of tissue counting of the SRDT pieces
was 761 (± 187, range 324-1114) minutes.
A same-day postoperative patient diagnostic PET/CT
scan was performed in 62 cases. Mean time from same-
day
18F-FDG injection to the same-day postoperative
patient diagnostic PET/CT scan was 516 (± 134, range
178-853) minutes.
Among the 142 patients who were taken to the oper-
ating room for
18F-FDG-directed surgery, 120 patients
were found to have histologic confirmation of malig-
nancy within their surgically resected specimens, 21
patients were found to have only benign pathology
within their surgically resected specimens that were
associated with their
18F-FDG-avid lesion(s) which
were originally seen on their preoperative patient PET/
CT scan, and one patient was intraoperatively found to
have no detectable 18F-FDG-avid lesion (as well as no
signs of disease on intraoperative ultrasound or on
intraoperative visual inspection and palpation). Four-
teen different histologic tumor types were represented
within surgically resected specimens removed at the
time of
18F-FDG-directed surgery from among the 120
patients with histologic confirmation of malignancy
(Table 2). The three most common histologic tumor
types found within surgically resected specimens were
colorectal carcinoma (n = 66, 55.0%), breast carcinoma
(n = 12, 10.0%), and lymphoma (n = 11, 9.2%). The
region of localization of these 14 histologic tumor
types among the 120 patients with histologic confirma-
tion of malignancy was the abdomen and/or pelvis
region in 87 cases (72.5%), the head and neck region
in 12 cases (10.0%), the extremity, axillary, or inguinal
regions in 12 cases (10.0%), and the chest region in 9
cases (7.5%).
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The aim of this paper was to comprehensively describe
the specific methodology utilized in our single-institu-
tion cumulative retrospective experience with a multi-
modal imaging and detection approach to
18F-FDG-
directed surgery for patients with known or suspected
malignancies. It is our belief that the information pre-
sented herein indicates that our multimodal imaging
and detection approach to
18F-FDG-directed surgery for
patients with known or suspected malignancies, utilizing
as a m e - d a y
18F-FDG injection dose, is feasible from
both a technical and a logistical perspective. This is evi-
dent from our ability to accomplish this coordination of
services by the surgeon, radiologist, and pathologist in a
same-day fashion. Such an integrated approach has the
potential for allowing for: (1) real-time intraoperative
staging of the extent of disease, (2) real-time intraopera-
tive surgical planning and execution of the necessary
and most appropriate operation, determination of the
extent of surgical resection, and determination of the
completeness of surgical resection, (3) real-time patholo-
gic evaluation of intact surgical resected specimens for
the confirmation of completeness of surgical resection
and for surgical margin assessment, and (4) real-time
pathologic evaluation of diagnostically biopsied tissues
for confirmation of correctness of tissue diagnosis [32].
Since this paper purely represents a comprehensive
description of the specific methodology utilized in our
single-institution cumulative retrospective experience
with a multimodal imaging and detection approach to
18F-FDG-directed surgery, and since this paper does not
detail the specific cumulative results amassed from these
145 individual cases, it is the future plan of our current
authorship to subsequently and systemically report upon
many different aspects of our results, including analysis
of image quality and sustainability of image quality seen
on same-day preoperative patient diagnostic PET/CT
imaging as it compares to same-day postoperative
patient diagnostic PET/CT imaging, clinical PET/CT
specimen imaging, micro PET/CT specimen imaging,
automatic gamma well counter specimen activity, and
intraoperative gamma probe assessment, as well as to
report upon future clinical relevance, future clinical
applications, and methodological limitations of this mul-
timodal imaging and detection approach to
18F-FDG-
directed surgery.
Whenever high-energy gamma photon emitting radio-
pharmaceuticals, such as
18F-FDG, are considered for
routine use in the operating room environment, it is of
importance to address the issue of radiation safety. In
this specific regard, we have previously evaluated the
occupational radiation exposure incurred by intraopera-
tive and perioperative personnel involved during
18F-
FDG-directed surgery cases [33]. In a comprehensive
evaluation of 10 actual
18F-FDG-directed surgery cases,
in which a mean dose of 18.9 mCi of
18F-FDG was
intravenously injected at a mean time of 142 minutes
prior to surgery, the resultant mean deep dose equiva-
lent per case for the surgeon, anesthetist, scrub technol-
ogist, postoperative nurse, circulating nurse, and
preoperative nurse was 164, 119, 92, 63, 54, and 48 μSv,
respectively. Based upon the established annual occupa-
tional exposure limit for adults within the United States
of a total effective dose equivalent of 50,000 μSv, as
defined by the United States Nuclear Regulatory Com-
mission [51], the estimated number of
18F-FDG-directed
surgery cases per year and the estimated number of
hours of exposure per year that could be theoretically
incurred by the surgeon, anesthetist, scrub technologist,
postoperative nurse, circulating nurse, and preoperative
nurse were 305 cases and 820 hours, 420 cases and
1020 hours, 543 cases and 2083 hours, 794 cases and
1471 hours, 926 cases and 2941 hours, and 1042 cases
and 602 hours, respectively. This data clearly illustrates
that the absorbed radiation dose received by both
intraoperative and perioperative personnel involved in
18F-FDG-directed surgery cases is relatively low per case
and allows for all such personnel to participate in multi-
ple cases and still remain well below regulatory stan-
dards set for occupational radiation exposure limits.
Conclusions
In summary, our multimodal imaging and detection
approach to
18F-FDG-directed surgery for patients with
known or suspected solid malignancies is technically
and logistically feasible. It can be accomplished with
Table 2 Fourteen histologic tumor types represented
within the surgically resected specimens removed at the
time of
18F-FDG-directed surgery from among the 120
patients with histologic confirmation of malignancy
Histologic tumor type Number (%) of patients
Colorectal carcinoma 66 (55.0%)
Breast carcinoma 12 (10.0%)
Lymphoma 11 (9.2%)
Ovarian carcinoma 7 (5.8%)
Head and neck squamous cell carcinoma 6 (5.0%)
Thyroid carcinoma 3 (2.5%)
Lung carcinoma 3 (2.5%)
Endometrial carcinoma 3 (2.5%)
Cervical carcinoma 2 (1.7%)
Melanoma 2 (1.7%)
Plasmacytoma 2 (1.7%)
Urothelial carcinoma 1 (0.8%)
Sarcoma 1 (0.8%)
Eccrine porocarcinoma 1 (0.8%)
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Page 8 of 10coordination of services provided by the surgeon, radiol-
ogist, and pathologist in a same-day fashion. This inte-
grated approach has the potential for allowing for real-
time intraoperative staging, surgical planning and execu-
tion, and determination of the completion of surgical
resection.
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